Get the Stockscreener App
0.2744
4.34%
-0.0156
Syros Pharmaceuticals Inc stock is traded at $0.2744, with a volume of 2.62M.
It is down -4.34% in the last 24 hours and down -87.62% over the past month.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
See More
Previous Close:
$0.29
Open:
$0.2898
24h Volume:
2.62M
Relative Volume:
0.36
Market Cap:
$7.17M
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.049
EPS:
-5.5956
Net Cash Flow:
$-103.90M
1W Performance:
+0.84%
1M Performance:
-87.62%
6M Performance:
-95.09%
1Y Performance:
-90.43%
1-Day Range:
$0.26
$0.2898
1-Week Range:
$0.183
$0.3735
52-Week Range:
$0.183
$8.17
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
617-744-1340
Address
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SYRS | 0.2745 | 7.17M | 9.94M | -144.49M | -103.90M | -5.5956 |
| VRTX | 448.35 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.89 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.59 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros pharmaceuticals chief development officer sells shares for $7,949 By Investing.com - Investing.com UK
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights
Syros Pharmaceuticals stock hits 52-week low at $0.4 By Investing.com - Investing.com Canada
JMP Securities cuts Syros Pharma stock to Market Perform - Investing.com
U.S. Stock market: Syros Pharmaceuticals(−86.21%), GlucoTrack(−77.70%) and others among the most volatile stocks during mid day trading - Business Upturn
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default - Benzinga
Syros Pharmaceuticals downgraded to Hold from Buy at TD Cowen - TipRanks
Syros Pharmaceuticals stock hits 52-week low at $0.4 - Investing.com
Syros stock craters after lead cancer therapy flops in Phase III trial - Pharmaceutical Technology
U.S. Stock market: Syros Pharmaceuticals surges by 680.00% while Spirit Airlines rises by 184.96% in early trading - Business Upturn
Syros flunks phase 3 blood cancer trial, triggering loan default and share-price plunge - Fierce Biotech
Syros Pharmaceuticals' (SYRS) Hold Rating Reiterated at Brookline Capital Management - MarketBeat
Analysts Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Target Price at $5.00 - MarketBeat
JMP Securities Reiterates Market Perform Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals' (SYRS) "Hold" Rating Reaffirmed at TD Cowen - MarketBeat
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure - MarketWatch
Syros Crashes Over 90% on Late-Stage MDS Fail, Loan Default - BioSpace
TD Cowen downgrades Syros Pharma stock to Hold on trial failure - Investing.com
Syros downgraded to Market Perform from Outperform at JMP Securities - TipRanks
HC Wainwright & Co. Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros stock dives 92% on failed Phase 3 study, possible loan default (update) - MSN
Syros Pharmaceuticals trial fails to meet primary goal - Investing.com
Syros Pharmaceuticals trial fails to meet primary goal By Investing.com - Investing.com UK
Syros Pharma Stock Alert: Phase 3 Trial Fails, Loan Default Triggered | SYRS Stock News - StockTitan
Syros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.com - MarketBeat
SYRS (Syros Pharmaceuticals) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Syros Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding from Incyte Corporation - Marketscreener.com
Incyte Corporation and yros Pharmaceuticals Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms - Marketscreener.com
SYRSW (Syros Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023) - Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results - MarketBeat
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress By Investing.com - Investing.com South Africa
Earnings call: Syros Pharmaceuticals outlines tamibarotene progress - Investing.com India
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ... - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Syros Pharmaceuticals (NASDAQ:SYRS) - MarketBeat
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Syros Pharmaceuticals Inc Stock (SYRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Roth David | Chief Medical Officer |
Nov 18 '24 |
Sale |
0.20 |
12,099 |
2,382 |
0 |
| Quirk Gerald E | Chief Legal & Compliance Offic |
Nov 19 '24 |
Sale |
0.22 |
46,657 |
10,321 |
0 |
| Chee Conley | President & CEO |
Nov 18 '24 |
Sale |
0.20 |
134,797 |
26,932 |
0 |
| Haas Jason | Chief Financial Officer |
Nov 18 '24 |
Sale |
0.21 |
137,803 |
28,980 |
0 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):